During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis as the main predictor of major adverse liver outcomes.
Read More > https://mash.pocn.com/treatment/liver-biopsy-evaluation-in-mash/
